Skip to main content
OpenTrials

Clinical trial condition

Hemorrhagic Disorders

Explore clinical trials studying Hemorrhagic Disorders. Study availability and eligibility vary by location and protocol.

4,576 public trials 831 recruiting studies
Refine in advanced search Browse all conditions

Hemorrhagic Disorders trial results

Recruiting

Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia

NCT05641142

Conditions
Cardiovascular Abnormalities, Cardiovascular Diseases, Congenital Abnormalities, +20 more
Locations
  • CHU d'Angers Angers, France
  • CHU de Bordeaux Bordeaux, France
  • Hôpital Ambroise Paré Boulogne-Billancourt, France
  • CHU de Caen Normandie Caen, France
View all 18 locations
View Trial Details
Recruiting

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

NCT07101328

Conditions
B-cell Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +23 more
Locations
  • City of Hope Duarte, California, United States
  • University of Colorado Denver - School of Medicine - Anschutz Medical Campus Aurora, Colorado, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Yale University School of Medicine - Yale Cancer Center New Haven, Connecticut, United States
View all 50 locations
View Trial Details
Recruiting

To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma

NCT07454187

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Henan Cancer Hospital Zhengzhou, Henan, China
  • The First Affiliated Hospital Of Soochow University Suzhou, Jiangsu, China
  • The Second Affiliated Hospital Of Xi an Jiaotong University (Xibei Hospital) Xi’an, Shanxi, China
  • The Second Affiliated Hospital Zhejiang University School Of Medicine Hangzhou, Zhejiang, China
View Trial Details
Recruiting

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

NCT05714839

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • GSK Investigational Site Bullhead City, Arizona, United States
  • GSK Investigational Site Pembroke Pines, Florida, United States
  • GSK Investigational Site Grand Rapids, Michigan, United States
  • GSK Investigational Site Chapel Hill, North Carolina, United States
View all 36 locations
View Trial Details
Recruiting

A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease

NCT06998524

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +8 more
Locations
  • UC Davis Sacramento, California, United States
  • University of Florida Gainesville, Florida, United States
  • University of Minnesota Medical Center Minneapolis, Minnesota, United States
  • Washington University School of Medicine St Louis, Missouri, United States
View all 28 locations
View Trial Details
Recruiting

A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

NCT06508983

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Beijing Chaoyang Hospital of Capital Medical University Beijing, Beijing Municipality, China
  • Guangzhou First People's Hospital Guangzhou, Guangdong, China
  • Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
  • First Affiliated Hospital of Henan University of Science and Technology Luoyang, Henan, China
View Trial Details
Recruiting

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

NCT06152575

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Infirmary Cancer Care Mobile, Alabama, United States
  • Western Regional Medical Center, Inc. dba. City of Hope Phoenix Goodyear, Arizona, United States
  • Beverly Hills Cancer Center Beverly Hills, California, United States
  • Clovis Community Medical Center Clovis, California, United States
View all 271 locations
View Trial Details
Recruiting

A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)

NCT07194850

Conditions
Autoimmune Diseases, Blood Coagulation Disorders, Blood Platelet Disorders, +22 more
Locations
  • Centre Hospitalier Universitaire de Bordeaux Groupe Hospitalier Pellegrin Hopital des Enfants Bordeaux, France
  • Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum (CVK) Berlin, Germany
  • Gaslini Children's Hospital Genoa, Italy
  • Fondazione IRCCS San Gerardo dei Tintori Monza, Italy
View all 20 locations
View Trial Details
Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

NCT05623020

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Jupiter Medical Center/Anderson Family Cancer Institute Jupiter, Florida, United States
  • MSK Basking Ridge Basking Ridge, New Jersey, United States
  • MSK Monmouth Middletown, New Jersey, United States
  • MSK Bergen Montvale, New Jersey, United States
View all 127 locations
View Trial Details

Related conditions